Skip to Main Content

Skip Nav Destination

Poster Sessions| November 16, 2004

CD6-Depleted Mobilized Stem Cells for Modification of HVG and GVH Reactions after HLA-Haploidentical Marrow Transplantation.

Hans-Jochem Kolb, MD,

Hans-Jochem Kolb, MD

¹Hematopoietic Cell Transplantation Dept. of Medicine 3, University of Munich, Munich, Germany ; ²CCG Hematopoietic Cell Transplantation, GSF-National Research Center for Environment and Health, Munich, Germany and ³Medical School Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil

Search for other works by this author on:

PubMed

Google Scholar

Iris Bigalke, MD,

Iris Bigalke, MD *

¹Hematopoietic Cell Transplantation Dept. of Medicine 3, University of Munich, Munich, Germany ; ²CCG Hematopoietic Cell Transplantation, GSF-National Research Center for Environment and Health, Munich, Germany and ³Medical School Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil

Search for other works by this author on:

PubMed

Google Scholar

Belinda Simoes, MD,

Belinda Simoes, MD *

¹Hematopoietic Cell Transplantation Dept. of Medicine 3, University of Munich, Munich, Germany ; ²CCG Hematopoietic Cell Transplantation, GSF-National Research Center for Environment and Health, Munich, Germany and ³Medical School Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil

Search for other works by this author on:

PubMed

Google Scholar

Christine Falk, PhD,

Christine Falk, PhD *

¹Hematopoietic Cell Transplantation Dept. of Medicine 3, University of Munich, Munich, Germany ; ²CCG Hematopoietic Cell Transplantation, GSF-National Research Center for Environment and Health, Munich, Germany and ³Medical School Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil

Search for other works by this author on:

PubMed

Google Scholar

Johanna Tischer, MD,

Johanna Tischer, MD *

¹Hematopoietic Cell Transplantation Dept. of Medicine 3, University of Munich, Munich, Germany ; ²CCG Hematopoietic Cell Transplantation, GSF-National Research Center for Environment and Health, Munich, Germany and ³Medical School Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil

Search for other works by this author on:

PubMed

Google Scholar

Wolfgang Hill, MD,

Wolfgang Hill, MD *

¹Hematopoietic Cell Transplantation Dept. of Medicine 3, University of Munich, Munich, Germany ; ²CCG Hematopoietic Cell Transplantation, GSF-National Research Center for Environment and Health, Munich, Germany and ³Medical School Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil

Search for other works by this author on:

PubMed

Google Scholar

Georg Ledderose, MD

Georg Ledderose, MD *

¹Hematopoietic Cell Transplantation Dept. of Medicine 3, University of Munich, Munich, Germany ; ²CCG Hematopoietic Cell Transplantation, GSF-National Research Center for Environment and Health, Munich, Germany and ³Medical School Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil

Search for other works by this author on:

PubMed

Google Scholar

Blood (2004) 104 (11): 978.

https://doi.org/10.1182/blood.V104.11.978.978

Abstract

Allogeneic stem cell transplantation is limited to patients with a histocompatible donor, but for patients with advanced acute leukemia and high-grade lymphoma HLA-haploidentical transplantation may be considered. Rejection of the transplant and graft-versus-host disease are major obstacles and T-cell depletion eliminates the graft-versus-leukemia effect and causes prolonged immune deficiency. Here we studied the use of CD6-depleted G-CSF mobilized blood cells (mbc) 6 days after transplantation of unmodified marrow in order to suppress host-versus-graft and graft-versus-host reactions (GVHD) retaining a graft-versus-leukemia effect and the capacity to reconstitute the immune system. CD6-depleted mbc contain a large proportion of NK and NK-T cells. 63 patients with advanced disease (AML 32, ALL 15, NHL 11, CLL 2, CML 2, SAA 1) were transplanted with marrow from family donors sharing one HLA-haplotype and differing in 0 – 4 HLA-antigens of the second haplotype. Conditioning consisted of total body irradiation (TBI), antithymocyte globulin (ATG) and cyclophosphamide (CY), post-grafting immunosuppression of cyclosporin A (CSA) and a short course of methotrexate (sMTX). A transfusion of donor leukocytes was given prior to CY. Complete engraftment was observed in 34 evaluable patients given 12 Gy TBI. The dose of TBI could be reduced to 4 Gy without rejection in 25 evaluable patients. GVHD was severe (grade III and IV) in 12 of 48 evaluable patients. An improved method of CD6-depletion was administered to mbc in 9 patients and severe GVHD did not develop. GVHD responded to corticosteroids in most patients. 15 patients survive disease free up to 6 years (median 784 days). Recurrent infections including PTLD were the major cause of transplant-related mortality. Absolute counts of lymphocytes, CD4 and CD8 subpopulations were not different from those of a contemporary group of 46 patients in advanced disease given HLA-identical sibling transplants. However naïve CD4 cells and TRECs were low. Rejection, GVHD and GVL have been controlled by this regimen, but immune reconstitution remains a problem that may be solved by early discontinuation of immunosuppression in this regimen.

Author notes

Corresponding author

2005, The American Society of Hematology

2004

Sign in via your Institution

Supplemental data